NCT01931163View on ClinicalTrials.gov

NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Breast CancerTriple Negative Breast Cancer
Interventions
DRUG

Everolimus

Trial Locations (3)

77030

The Methodist Hospital, Houston

77070

Houston Methodist Hospital Willowbrook, Houston

77479

Houston Methodist Hospital Sugar Land, Sugar Land

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

lead

Jenny C. Chang, MD

OTHER

NCT01931163 - NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer | Biotech Hunter | Biotech Hunter